Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Leela Sarukkai"'
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplementary Table 5. Outcome for KIT E8+ mutation positive patients according to treatment arm (No GO vs. GO)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3966b178badc4203ce66d03090b9e5e9
https://doi.org/10.1158/1078-0432.22473624
https://doi.org/10.1158/1078-0432.22473624
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplementary Table 2. Clinical outcomes for patients with CBF AML according to E17+ vs KIT- mutational status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0718c442815bdb96087d146c7a0b20fe
https://doi.org/10.1158/1078-0432.22473633
https://doi.org/10.1158/1078-0432.22473633
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplementary Table 3. Outcome for KIT E17+ mutation positive patients according to treatment arm (No GO vs. GO)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237d8f57432b8575173eb3d1589e9454
https://doi.org/10.1158/1078-0432.22473630
https://doi.org/10.1158/1078-0432.22473630
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Purpose:KIT mutations (KIT+) are common in core binding factor (CBF) AML and have been associated with varying prognostic significance. We sought to define the functional and clinical significance of distinct KIT mutations in CBF pediatric AML.Experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9860ab06204f027f3d41754b27b9e08e
https://doi.org/10.1158/1078-0432.c.6528567
https://doi.org/10.1158/1078-0432.c.6528567
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplemental Figure 2. Functional Evaluation and TKI response of E11 mutations. (A) Evaluation of the phosphorylation status of KIT following transfection of the mutations in exon 11, V559D and L576P, into HEK293 cell line. (B) IL-3 independent growt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b46e0a5b8e40db5a951794f95fcdfc
https://doi.org/10.1158/1078-0432.22473642.v1
https://doi.org/10.1158/1078-0432.22473642.v1
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplemental Figure 1. (A) KIT mutational status of the cohort; (B) Prevalence of CBF subtype among the E8 and E17 mutations. (B) Among E8 mutations, 54% of patients were inv(16) and 46% were t(8;21). (C) Among E17 mutations, 37% of patients were inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::093fcbac102a63071c819c06ef756a60
https://doi.org/10.1158/1078-0432.22473645
https://doi.org/10.1158/1078-0432.22473645
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplementary Table 1. Clinical and biologic characteristics of CBF patients treated on COG AAML0531 stratified by KIT mutational status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22e41e0ee1556164798f4b5bd68a116d
https://doi.org/10.1158/1078-0432.22473636.v1
https://doi.org/10.1158/1078-0432.22473636.v1
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplementary Table 4. Clinical outcomes for patients with CBF AML according to E8+ vs KIT- mutational status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a6947f3dd020797fcbd6c5914a0a78
https://doi.org/10.1158/1078-0432.22473627.v1
https://doi.org/10.1158/1078-0432.22473627.v1
Autor:
Jessica A. Pollard, Soheil Meshinchi, Alan S. Gamis, Irwin Bernstein, Richard Aplenc, Lillian Sung, Betsy Hirsch, Susana C. Raimondi, Leela Sarukkai, Jason Joaquin, Tiffany Hylkema, Laura Pardo, Michael R. Loken, Rhonda Ries, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Katherine Tarlock
Supplementary Figure 3. CD117 expression as measured by MFI of Ba/F3 cell lines transduced with KIT-WT as well E17, E8, and E11 KIT mutations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b8ccee3d5209ac8cefb2afa9a360fc
https://doi.org/10.1158/1078-0432.22473639.v1
https://doi.org/10.1158/1078-0432.22473639.v1
Autor:
Tiffany A. Hylkema, Irwin D. Bernstein, Jessica A. Pollard, Michael R. Loken, Todd A. Alonzo, Laura Pardo, Alan S. Gamis, Richard Aplenc, Soheil Meshinchi, Lillian Sung, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Rhonda E. Ries, Leela Sarukkai, Katherine Tarlock, Yi-Cheng Wang, Jason Joaquin
Publikováno v:
Clinical Cancer Research. 25:5038-5048
Purpose: KIT mutations (KIT+) are common in core binding factor (CBF) AML and have been associated with varying prognostic significance. We sought to define the functional and clinical significance of distinct KIT mutations in CBF pediatric AML. Expe